Prevalence of daily or near daily aspirin use by US adults with diabetes: A cross-sectional study using a multi-year national database


Introduction: For persons with diabetes, cardiovascular disease is the major cause of morbidity and mortality that is reflected in a two-to- four times greater risk for both heart disease and stroke when compared to adults without diabetes. Although not without controversy, diabetes and cardiovascular disease (CVD) management guidelines in the US recommend the use of once-daily aspirin. This epidemiological study was undertaken to fill the knowledge gap regarding the prevalence of daily or near daily aspirin use for US age-appropriate adults with diabetes. Methods: Using bivariate and multivariate techniques, a cross-sectional analysis of an amalgamated database using 2005, 2007, and 2009 Behavioral Risk Factor Surveillance Survey data was performed. The dependent variable for this analysis was daily or near daily aspirin use. The population of interest was US adults, men >= 45 - 79 and women >= 55 - 79 years of age. Results: Overall the prevalence of daily or near daily aspirin use by age-appropriate US adults with diabetes was 62.5%; it was 41.0% for similar non-diabetic adults. Logistic regression analysis yielded that age-appropriate adults, of both genders, with diabetes taking daily or near daily aspirin were more likely to be: physically active, male, live in rural locales, not have a health care provider, have deferred medical care because of cost, have an elevated BMI, a smoker, and have hypertension. Conclusion: It was determined that the age-appropriate use of aspirin in the US adult population with diabetes is underutilized. The role of the pharmacist through- out the continuum of care is one way to improve appropriate aspirin use in patients with diabetes.

Share and Cite:

F. Akers, M. , Lutfiyya, M. , L. Amaro, M. and Swanoski, M. (2012) Prevalence of daily or near daily aspirin use by US adults with diabetes: A cross-sectional study using a multi-year national database. Health, 4, 297-303. doi: 10.4236/health.2012.46049.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] American Diabetes Association (2011) Position statement: Standards of medical care in diabetes—2011. Diabetes Care, 34, S11-S61.
[2] American Diabetes Association, c1995-2011. Statistics.
[3] Lloyd-Jone, D., Adams, R.J., Brown, T.M., Carnethon, M., Dai, S., De Simone, G., et al. (2010) Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation, 121, e46-e215. doi:10.1161/CIRCULATIONAHA.109.192667
[4] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation, 106, 31433421.
[5] Laakso, M. (2010) Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care, 33, 442-449. doi:10.2337/dc09-0749
[6] Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E., Mukherjee, D., et al. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation, 121, 2694-2701. doi:10.1161/CIR.0b013e3181e3b133
[7] US Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Annals of Internal Medicine, 136, 157-160.
[8] Stafford, R.S., Monti, V. and Ma, J. (2005) Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Medicine, 2, e353. doi:10.1371/journal.pmed.0020353
[9] Rolka, D.B., Fagot-Campagna, A. and Narayan, K.M. (2001) Aspirin use among adults with diabetes. Diabetes Care, 24, 197-201. doi:10.2337/diacare.24.2.197
[10] Lee, H.Y., Tong, Y.P., Xing, S. and Cooke, C.E. (2010) Aspirin use in elderly women receiving medication therapy management services. Advances in Therapy, 27, 613622. doi:10.1007/s12325-010-0046-1
[11] Brown, D.W., Shepard, D., Giles, W.H., Greenlund, K.J. and Croft, J.B. (2005) Racial differences in the use of aspirin: An important tool for preventing heart disease and stroke. Ethnicity and Disease, 15, 620-626.
[12] Berlie, H.D., Hammad, A. and Jaber, L.A. (2007) The use of glucose-lowering agents and aspirin among Arab Americans with diabetes. Ethnicity and Disease, 17, 4245.
[13] Lee, R., Onopa, J., Mau, M.K. and Seto, T.B. (2010) Diabetes care in a predominantly Native Hawaiian and Pacific Islander outpatient population. Hawaii Medical Journal, 69, 28-30.
[14] Sanchez, D.R., Diez-Roux, A.V., Michos, E.D., Blumenthal, R.S., Schreiner, P.J., Burke, G.L. and Watson, K. (2011) Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of Atherosclerosis. American Journal of Cardiology, 107, 41-46. doi:10.1016/j.amjcard.2010.08.041
[15] Mokdad, A.H., Stroup, D.F. and Giles, W.H. (2003) Public health surveillance for behavioral risk factors in a changing environment: Recommendations from the behavioral risk factor surveillance team. Morbidity and Mortality Weekly Report, 52, RR09.
[16] Antithrombotic Trialists’ (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 18491860. doi:10.1016/S0140-6736(09)60503-1
[17] Buse, J.B., Ginsberg, H.N., Bakris, G.L., Clark, N.G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H.C., Grundy, S., Nesto, R.W., Pignone, M.P., Plutzky, J., Porte, D., Redberg, R., Stitzel, K.F. and Stone, N.J. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115, 114-126. doi:10.1161/CIRCULATIONAHA.106.179294
[18] Link, B.G. and Phelan, J.C. (1996) Editorial: Understanding sociodemographic differences in health-the role of fundamental social causes. American Journal of Public Health, 86, 471-473. doi:10.2105/AJPH.86.4.471
[19] Smith, M., Bates, D.W., Bodenheimer, T. and Cleary, P.D. (2010) Why pharmacists belong in the medical home. Health Affairs, 29, 906-913. doi:10.1377/hlthaff.2010.0209
[20] Goode, K.R. (2006) Change in community pharmacy practice—It is not just coming from the cash register. US Pharmacy Review.
[21] Krantz, M.J., Berger, J.S. and Hiatt, W.R. (2010) An aspirin a day: Are we barking up the wrong willow tree? Pharmacotherapy, 30, 115-118. doi:10.1592/phco.30.2.115

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.